Treatment With 25-Hydroxyvitamin D(3) (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-to-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With COVID-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial

OBJECTIVE: The goal of this randomized, double-blinded, placebo-controlled clinical trial was to investigate the therapeutic efficacy of oral 25-hydroxyvitamin D(3) (25(OH)D(3)) in improving vitamin D status in vitamin D–deficient/vitamin D–insufficient patients infected with the SARS-CoV-2 (COVID-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Maghbooli, Zhila, Sahraian, Mohammad Ali, Jamalimoghadamsiahkali, Saeidreza, Asadi, Asma, Zarei, Azadeh, Zendehdel, Abolfazl, Varzandi, Tarlan, Mohammadnabi, Sara, Alijani, Neda, Karimi, Mehrdad, Shirvani, Arash, Holick, Michael F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AACE. Published by Elsevier Inc. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511889/
https://www.ncbi.nlm.nih.gov/pubmed/34653608
http://dx.doi.org/10.1016/j.eprac.2021.09.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511889/
https://www.ncbi.nlm.nih.gov/pubmed/34653608
http://dx.doi.org/10.1016/j.eprac.2021.09.016

Ejemplares similares